<--- Back to Details
First PageDocument Content
Chemistry / Biochemistry / Biology / Metabolism / Cellular respiration / Metabolic pathways / Anaplerotic reactions / Citric acid cycle / Biosynthesis / Dehydrogenase / Pyruvate kinase / Alpha-Ketoglutaric acid
Date: 2016-03-11 05:10:37
Chemistry
Biochemistry
Biology
Metabolism
Cellular respiration
Metabolic pathways
Anaplerotic reactions
Citric acid cycle
Biosynthesis
Dehydrogenase
Pyruvate kinase
Alpha-Ketoglutaric acid

Seminar 2  Isotope tracing    13​ Q: ​ How many possible ​

Add to Reading List

Source URL: www.nilssonlab.se

Download Document from Source Website

File Size: 280,59 KB

Share Document on Facebook

Similar Documents

Seminar 2  Isotope tracing    13​ Q: ​ How many possible ​

Seminar 2  Isotope tracing    13​ Q: ​ How many possible ​

DocID: 1rtZ3 - View Document

All reactions strive to minimize energy Energy barrier of intermediates determine reaction rate

All reactions strive to minimize energy Energy barrier of intermediates determine reaction rate

DocID: 1owXo - View Document

The Immune-Metabolic Basis of Effector Memory CD4 + T Cell Function under Hypoxic Conditions This information is current as of December 17, 2015.

The Immune-Metabolic Basis of Effector Memory CD4 + T Cell Function under Hypoxic Conditions This information is current as of December 17, 2015.

DocID: 1mYvr - View Document

Recommendations by The International Bengal Cat Society, IncErythrocyte Pyruvate Kinase Deficiency (PK Deficiency) Testing and Breeding Erythrocyte Pyruvate Kinase Deficiency (PK Deficiency) is an inherited hem

Recommendations by The International Bengal Cat Society, IncErythrocyte Pyruvate Kinase Deficiency (PK Deficiency) Testing and Breeding Erythrocyte Pyruvate Kinase Deficiency (PK Deficiency) is an inherited hem

DocID: 1m5JE - View Document

Opportunity  Combination of mutant BRAF inhibitor with Pyruvate Dehydrogenase Kinase isoform 1 (PDK-1) inhibitor for treatment of melanoma/ overcoming BRAF inhibitor resistance •

Opportunity Combination of mutant BRAF inhibitor with Pyruvate Dehydrogenase Kinase isoform 1 (PDK-1) inhibitor for treatment of melanoma/ overcoming BRAF inhibitor resistance •

DocID: 1apbE - View Document